I agree that this site is using cookies. You can find further informations here.
X
Marschner, Jens-Peter
98  results:
Search for persons X
?
1

ATX-101, a cell-penetrating protein targeting PCNA, can be ..:

Lemech, Charlotte Rose ; Kichenadasse, Ganessan ; Marschner, Jens-Peter...
Oncogene.  42 (2022)  7 - p. 541-544 , 2022
Link: https://doi.org/10.1038/..
 
?
2

ATX-101, a cell-penetrating protein targeting PCNA, can be ..:

Lemech, Charlotte Rose ; Kichenadasse, Ganessan ; Marschner, Jens-Peter...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918429/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
3

A phase 1 study of the bispecific anti-CD30/CD16A antibody ..:

Rothe, Achim ; Sasse, Stephanie ; Topp, Max S...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4528081/.  , 2015
Link: http://www.ncbi.nlm.nih...
 
?
4

EGFRvIII TandAbs are specific and highly potent drug candid..:

Ellwanger, Kristina ; Reusch, Uwe ; Fucek, Ivica...
http://www.immunotherapyofcancer.org/content/3/S2/P219.  , 2015
Link: http://www.immunotherapy..
 
?
5

Defining the critical hurdles in cancer immunotherapy:

Fox, Bernard ; Schendel, Dolores ; Butterfield, Lisa...
info:eu-repo/semantics/altIdentifier/doi/10.1186/1479-5876-9-214.  , 2011
Link: https://inserm.hal.scien..
 
?
6

Defining the critical hurdles in cancer immunotherapy:

Fox, Bernard ; Schendel, Dolores ; Butterfield, Lisa...
info:eu-repo/semantics/altIdentifier/doi/10.1186/1479-5876-9-214.  , 2011
Link: https://www.hal.inserm.f..
 
?
7

Defining the critical hurdles in cancer immunotherapy:

Fox, Bernard ; Schendel, Dolores ; Butterfield, Lisa...
info:eu-repo/semantics/altIdentifier/doi/10.1186/1479-5876-9-214.  , 2011
Link: https://inserm.hal.scien..
 
?
8

Defining the critical hurdles in cancer immunotherapy:

Fox, Bernard ; Schendel, Dolores ; Butterfield, Lisa...
info:eu-repo/semantics/altIdentifier/doi/10.1186/1479-5876-9-214.  , 2011
Link: https://inserm.hal.scien..
 
?
9

Defining the critical hurdles in cancer immunotherapy:

Fox Bernard A ; Schendel Dolores J ; Butterfield Lisa H...
http://www.translational-medicine.com/content/9/1/214.  , 2011
Link: https://doi.org/10.1186/..
 
?
10

Defining the Critical Hurdles in Cancer Immunotherapy:

Fox, Bernard A ; Schendel, Dolores J ; Butterfield, Lisa H...
qt34d0r2jw.  , 2011
Link: https://escholarship.org..
 
?
11

Defining the critical hurdles in cancer immunotherapy:

Fox, Bernard ; Schendel, Dolores ; Butterfield, Lisa...
info:eu-repo/semantics/altIdentifier/doi/10.1186/1479-5876-9-214.  , 2011
Link: https://inserm.hal.scien..
 
?
12

Defining the Critical Hurdles in Cancer Immunotherapy:

Fox, B.A. (Bernard A.) ; Schendel, D. J. (Dolores J.) ; Butterfield, L.H. (Lisa H.)...
http://www.translational-medicine.com/content/9/1/214/abstract.  , 2011
Link: https://hdl.handle.net/1..
 
?
13

Efficacy and safety of an intravenous monoclonal anti-HBs i..:

Nunen, A.B. van ; Baumann, M. (Marc) ; Manns, M.P. (Michael)...
http://repub.eur.nl/pub/66667.  , 2001
Link: http://repub.eur.nl/pub/..
 
?
14

Integration of p16/HPV DNA Status with a 24-miRNA-Defined M..:

Hess, Julia ; Unger, Kristian ; Maihoefer, Cornelius...
Cancers.  14 (2022)  15 - p. 3745 , 2022
Link: https://doi.org/10.3390/..
 
?
15

GPCR-specific autoantibody signatures are associated with p..:

Cabral-Marques, Otavio ; Marques, Alexandre ; Giil, Lasse Melvær...
Nature Communications.  9 (2018)  1 - p. , 2018
Link: https://doi.org/10.1038/..
 
1-15